EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, TransMedics Group's enterprise value is $3,095.2 Mil.
TransMedics Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.7 Mil. Therefore, TransMedics Group's EV-to-EBITDA for today is -401.81.
The historical rank and industry rank for TransMedics Group's EV-to-EBITDA or its related term are showing as below:
TMDX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -404.87 Med: -25.16 Max: -7.17
Current: -401.81
During the past 8 years, the highest EV-to-EBITDA of TransMedics Group was -7.17. The lowest was -404.87. And the median was -25.16.
TMDX's EV-to-EBITDA is ranked worse than 100% of 487
companies
in the Medical Devices & Instruments industry
Industry Median: 15.1
vs TMDX: -401.81
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-24), TransMedics Group's stock price is $88.88.
TransMedics Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.770. Therefore, TransMedics Group's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
TransMedics Group EV-to-EBITDA Historical Data
The historical data trend for TransMedics Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of TransMedics Group's EV-to-EBITDA
For the Medical Devices subindustry, TransMedics Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransMedics Group's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where TransMedics Group's EV-to-EBITDA falls into.
TransMedics Group EV-to-EBITDA Calculation
TransMedics Group's EV-to-EBITDA for today is calculated as:
TransMedics Group's current Enterprise Value is $3,095.2 Mil.
TransMedics Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransMedics Group (NAS:TMDX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
TransMedics Group's PE Ratio for today is calculated as:
TransMedics Group's share price for today is $88.88.
TransMedics Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.770.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of TransMedics Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
TransMedics Group (TransMedics Group) Business Description
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TMDX has been successfully added to your 